mellitus in Chinese women: a prospective study of 16, 286 pregnant women in China[J]. Diabet Med, 2009, 26:1099-1104. [29] 王爱红，许樟荣，纪立农．中国城市医院糖尿病截肢的临 床特点及医疗费用分析 [J]．中华医学杂志， 2012， 92 ： 224-227．
[30] 钱荣立．加强对糖尿病慢性并发症的防治研究 [J]．中国糖 尿病杂志， 2003， 11 ： 231．
[31] 张昕，沈水仙，罗飞宏，等．上海市卢湾区青少年 2 型糖尿 病患病率调查 [J]．中国循证儿科杂志， 2006， 1 ： 204-209． [32] 曹冰燕，米杰，巩纯秀，等．北京市 19 593 名儿童青少年 糖尿病患病现况调查 [J]．中华流行病学杂志， 2007， 28 ： 631-634．
[33] 中华医学会糖尿病学分会慢性并发症调查组． 1991 ～ 2000 年全国住院糖尿病患者慢性并发症及相关大血管病变回顾 性分析 [J]．中国医学科学院学报， 2002， 24 ： 447-451．
[34] Hu DY, Pan CY, Yu JM, et al. The relationship between coronary artery disease and abnormal glucose regulation in China: the China Heart Survey[J]. Eur Heart J, 2006, 27:2573-2579.
[35] Alberti KG, Zimmet PZ. Defnition, diagnosis and classifcation of diabetes mellitus and its complications. Part 1: diagnosis and
《中国医学前沿杂志（电子版）》 2015 年第 7 卷第 3 期 ● 中国
循证指南共识 ● 79
classifcation of diabetes mellitus provisional report of a WHO consultation[J]. Diabet Med, 1998, 15:539-553.
[36] World Health Orgnization. Defnition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation, 2006[M]. Geneva: WHO Document Production Services, 2006.
[37] Diagnostic criteria and classification of hyperglycaemia first
detected in pregnancy: a World Health Organization Guideline[J]. Diabetes Res Clin Pract, 2014, 103:341-363.
[38] World Health Orgnization. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Abbreviated report of a WHO consultation, 2011[EB/OL]. (2011-01-13) [2013-11-12]. http://who.int/diabetes/publications/report-hba1c-2011.pdf. [39] 中华人民共和国卫生部．中华人民共和国卫生行业标 准 -WS331-2011妊娠期糖尿病诊断 [J]．中华围产医学杂志， 2012， 15 ： 100．
[40] International Expert Committee. International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes[J]. Diabetes Care, 2009, 32:1327-1334.
[41] American Diabetes Association. Diagnosis and classifcation of diabetes mellitus[J]. Diabetes Care, 2010, 33 Suppl 1:S62-69. [42] The International Diabetes Federation Consensus Workshop.
Type 2 diabetes in the young: the evolving epidemic[J]. Diabetes Care, 2004, 27:1798-1811.
[43] Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study[J]. Lancet, 2008, 371:1783-1789.
[44] Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin[J]. N Engl J Med, 2002, 346:393-403.
[45] Tuomilehto J, Lindstrm J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance[J]. N Engl J Med, 2001, 344:1343-1350. [46] Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised
trial[J]. Lancet, 2002, 359:2072-2077.
[47] Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials[J]. Lancet, 2010, 375:735-742.
[48] Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes
with intensive-dose compared with moderate-dose statin therapy: a meta-analysis[J]. JAMA, 2011, 305:2556-2564.
[49] 中华人民共和国卫生行业标准（ WS397-2012）．糖尿病 筛查和诊断 [S]．（ 2012-09-05） [2013-11-22]． http://www. moh.gov.cn/zwgkzt/s9492/201209/55981.shtml.
[50] Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study[J]. Lancet, 2009, 374:1677-1686.
[51] Zhou X, Qiao Q, Ji L, et al. Nonlaboratory-based risk assess ment
algorithm for undiagnosed type 2 diabetes developed on a nationwide diabetess urvey[J]. Diabetes Care, 2013, 36:3944-3952.
[52] Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study[J]. Diabetes Care, 1997, 20:537-544.
[53] Lindstrm J, Ilanne-Parikka P, Peltonen M, et al. Sustained
reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study[J]. Lancet, 2006, 368:1673-1679.
[54] Lian F, Li G, Chen X, et al. Chinese herbal medicine Tianqi reduces progression from impaired glucose tolerance to diabetes: a double-blind, randomized, placebo-controlled, multicenter trial[J]. J Clin Endocrinol Metab, 2014, 99:648-655.
[55] Mc Murray JJ, Holman RR, Haffner SM, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events[J]. N Engl J Med, 2010, 362:1477-1490.
[56] Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes[J]. N Engl J Med, 2005, 353:2643-2653.
[57] Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes[J]. N Engl J Med, 2008, 359:1577-1589.
[58] UK Prospective Diabetes Study Group. Tight blood pressure
control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38[J]. BMJ, 1998, 317:703-713.
[59] Snow V, Weiss KB, Mottur-Pilson C, et al. The evidence base for tight blood pressure control in the management of type 2 diabetes mellitus[J]. Ann Intern Med, 2003, 138:587-592.
[60] Collins R, Armitage J, Parish S, et al. Heart Protection Study collaborative group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial[J]. Lancet, 2003, 361:2005-2016.
[61] Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastat in Diabetes Study (CARDS): multicentre randomized placebo-controlled trial[J]. Lancet, 2004, 364:685-696.
[62] Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus[J]. N Engl J Med, 2010, 362:1563-1574.
[63] Zhang C, Sun A, Zhang P, et al. Aspirin for primary prevention
of cardiovascular events in patients with diabetes: a meta-analysis[J]. Diabetes
Res Clin Pract, 2010, 87:211-218.
[64] Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes[J]. N Engl J Med, 2008, 358:2560-2572.
[65] Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes[J]. N Engl J Med, 2008, 358:2545-2559.
[66] Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes[J]. N Engl J Med, 2009, 360:129-139.
[67] Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes[J]. N Engl J Med, 2008, 358:580-591.
[68] DREAM Trial Investigators. Effect of rosiglitazone on the
80 ● 中国循证指南共识 ● 《中国医学前沿杂志（电子版）》2015 年第 7 卷第 3 期
frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: arandomised controlled trial[J]. Lancet, 2006, 368:1096-1105.
[69] DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance[J]. N Engl J Med, 2011, 364:1104-1115.
[70] Zinman B, Harris SB, Neuman J, et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study[J]. Lancet, 2010, 376:103-111.
[71] Ramachandran A, Snehalatha C, Mary S, et al. The Indian
Diabetes Prevention Programme shows that lifestyle modifcation and metformin prevent type 2 diabetes in Asian Indian
subjects with impaired glucose tolerance (IDPP-1)[J]. Diabetologia, 2006, 49:289-297.
[72] Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese sub jects (XENDOS) study:
a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients[J]. Diabetes Care, 2004, 27:155-161.
[73] Gillies CL, Abrams KR, Lambert PC, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis[J]. BMJ, 2007, 334:299.
[74] Renders CM, Valk GD, Griffn SJ, et al. Interventions to improve the management of diabetes in primary care, outpatient, and community settings: a systematic review[J]. Diabetes Care, 2001, 24:1821-1833.
[75] Brown SA. Effects of educational interventions in diabetes care: a meta-analysis of fndings[J]. Nurs Res, 1988, 37:223-230.
[76] Brown SA. Meta-analysis of diabetes patient education research: variationsin in tervention effects across studies[J]. Res Nurs Health, 1992, 15:409-419.
[77] Guerci B, Drouin P, Grangé V, et al. Self-monitoring of blood glucose significantly improves metabolic control in patients with type 2 diabetes mellitus: the Auto-Surveillance Intervention Active (ASIA) study[J]. Diabetes Metab, 2003, 29:587-594. [78] American Diabetes Association: Standards of medical care in diabetes-2013[J]. Diabetes Care, 2013, 36 Suppl 1:S11-66. [79] Wadden TA, Neiberg RH, Wing RR, et al. Four-year weight
losses in the Look AHEAD Study: factors associated with longterm success[J]. Obesity (Silver Spring), 2011, 19:1987-1998.
[80] 中华人民共和国国家卫生和计划生育委员会．成人糖尿病 患者膳食指导 [M]．北京 ：中国标准出版社， 2013．
[81] Foster GD, Wyatt HR, Hill JO, et al. Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: a randomized trial[J]. Ann Intern Med, 2010, 153:147-157. [82] Salas-Salvadó J, Bulló M, Babio N, et al. Reduction in the incidence of type 2 diabetes with the Mediterranean diet:results of the PREDIMED-Reus nutrition intervention randomized trial[J]. Diabetes Care, 2011, 34:14-19.
[83] Malik VS, Popkin BM, Bray GA, et al. Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: a
meta-analysis[J]. Diabetes Care, 2010, 33:2477-2483.
[84] Wheeler ML, Dunbar SA, Jaacks LM, et al. Macronutrients, food groups, and eating patterns in the management of diabetes: a systematic review of the literature, 2010[J]. Diabetes Care, 2012, 35:434-445.
[85] Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and ascientifc statement of the American College of Cardiology Foundation and the American Heart Association[J]. J Am Coll Cardiol, 2009, 53:298-304.
[86] Greenfeld S, Billimek J, Pellegrini F, et al. Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: a cohort study[J]. Ann Intern Med, 2009, 151:854-860.
[87] UK Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type Ⅱ diabetes: a progressive disease[J]. Diabetes, 1995, 44:1249-1258.
[88] The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus[J]. N Engl J Med, 1993, 329:977-986.
[89] Shichiri M, Kishikawa H, Ohkubo Y, et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients[J]. Diabetes Care, 2000, 23 Suppl :S21-29. [90] Bailey CJ, Turner RC. Metformin[J]. N Engl J Med, 1996, 334:574-579.
[91] Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes[J]. Nihon Rinsho, 2012, 70 Suppl 3:S591-601.
[92] Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control[J]. Endocr Pract, 2009, 15:540-559.
[93] 祝方，纪立农，韩学尧，等．短期胰岛素强化治疗诱导初 诊 2 型糖尿病患者血糖长期良好控制的临床试验 [J]．中国 糖尿病杂志， 2003， 11 ： 5-9．
[94] 翁建平，李延兵，许雯，等．短期持续胰岛素输注治疗对 初诊 2 型糖尿病患者胰岛 β 细胞功能的影响 [J]．中国糖尿 病杂志， 2003， 11 ： 10-15．
[95] Li Y, Xu W, Liao Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated
with improvement of beta-cell function[J]. Diabetes Care, 2004, 27:2597-2602.
[96] Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly
diagnosed type 2 diabetes: a multicentre randomized parallelgrouptrial[J]. Lancet, 2008, 371:1753-1760.
[97] Boulé NG, Haddad E, Kenny GP, et al. Effects of exercise on glycemic control and body massin type 2 diabetes mellitus:
《中国医学前沿杂志（电子版）》 2015 年第 7 卷第 3 期 ● 中国
循证指南共识 ● 81
a meta-analysis of controlled clinical trials[J]. JAMA, 2001, 286:1218-1227.
[98] Snowling NJ, Hopkins WG. Effects of different modes of
exercise training on glucose control and risk factors for comp lications in type 2 diabetic patients: a meta-analysis[J]. Diabetes Care, 2006, 29:2518-2527. [99] Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus[J]. Ann Intern Med, 2007, 147:386-399.
[100] Sherifali D, Nerenberg K, Pullenayegum E, et al. The effect of oral antidiabetic agents on A1c levels: a systematic review and meta-analysis[J]. Diabetes Care, 2010, 33:1859-1864.
[101] DeFronzo RA, Goodman AM, the Multicenter Metformin Study
Group. Effcacy of metforminin patients with non-insulin-dependent diabetes mellitus[J]. N Engl J Med, 1995, 333:541-549.
[102] Saenz A, Fernandez-Esteban I, Mataix A, et al. Metformin
monotherapy for type 2 diabetes mellitus[J]. Cochrane Database Syst Rev, 2005, 20:CD002966.
[103] UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS34)[J]. Lancet, 1998, 352:854-865.
[104] Salpeter S, Greyber E, Pasternak G, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus[J]. Cochrane Database Syst Rev, 2010:CD002967. [105] Groop LC. Sulfonylureas in NIDDM[J]. Diabetes Care, 1992, 15:737-747.
[106] 杨兆军，杨文英，吕肖锋，等．二甲双胍与格列喹酮或阿 卡波糖联合治疗 2 型糖尿病的临床疗效和安全性比较 ：多 中心、随机、开放、平行分组对照研究 [J]．中华糖尿病杂 志， 2009， 1 ： 170-173．
[107] Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy[J]. N Engl J Med, 2006, 355:2427-2443.
[108] Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes[J]. N Engl J Med, 2007, 356:2457-2471.
[109] Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis[J]. JAMA, 2007, 298:1189-1195.
[110] Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomized clinical trials[J]. Lancet, 2007, 370:1129-1136. [111] Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death[J]. Ann Intern Med, 2007, 147:578-581.
[112] UK Prospective Diabetes Study Group. Intensive blood glucose
control with sulphonylureas or insulin compared with conventional treatment and
risk of complications in patients with type 2 diabetes (UKPDS33)[J]. Lancet, 1998, 352:837-853.
[113] Marre M, VanGaal L, Usadel KH, et al. Nateglinide improves glycaemic control when added to metformin monotherapy:
results of a randomized trial with type 2 diabetes patients[J]. Diabetes Obes Metab, 2002, 4:177-186.
[114] Malaisse WJ. Pharmacology of the meglitinide analogs: new
treatment options for type 2 diabetes mellitus[J]. Treat Endocrinol, 2003, 2:401-414.
[115] Moses RG, Gomis R, Frandsen KB, et al. Flexiblemeal-related dosing with repaglinide facilitates glycemic control in therapy na?ve type 2 diabetes[J]. Diabetes Care, 2001, 24:11-15.
[116] Raskin P, Klaff L, McGill J, et al. Effcacy and safety of combination therapy: repaglinide plus metformin versus nategl inide plus metformin[J]. Diabetes Care, 2003, 26:2063-2068.
[117] Fonseca V, Grunberger G, Gupta S, et al. Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control[J]. Diabetes Care, 2003, 26:1685-1690.
[118] Gerich J, Raskin P, Jean-Louis L, et al. PRESERVE-beta: twoyear efficacy and safety of initial combination therapy with
nateglinide orglyburide plus metformin[J]. Diabetes Care, 2005, 28:2093-2099.
[119] Chan JC, Chan KW, Asian Acarbose Study Group, et al. An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet[J]. Diabetes Care, 1998, 21:1058-1061.
[120] Van de Laar FA, Lucassen PL, Akkermans RP, et al. Alphaglucosidase inhibitors for type 2 diabetes mellitus[J]. Cochrane Database Syst Rev, 2005, 18:CD003639.
[121] Baggio LL, Drucker DJ. Biology of incretions: GLP-1 and GIP[J]. Gastroenterology, 2007, 132:2131-2157.
[122] Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes[J]. Lancet, 2006, 368:1696-1705.
[123] Hermansen K, Kipnes M, Luo E, et al. Effcacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin[J]. Diabetes Obes Metab, 2007, 9:733-745.
[124] Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin
therapy in type 2 diabetes: systematic review and metaanalysis[J]. JAMA, 2007, 298:194-206.
[125] Nauck MA, Vilsboll T, Gallwitz B, et al. Incretin-based therapies: view points to the way to consensus[J]. Diabetes Care, 2009, 32 Suppl 2:S223-231.
[126] DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes[J]. Diabetes Care, 2005, 28:1092-1100.
[127] Mohan V, Yang W, Son HY, et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea[J]. Diabetes Res Clin Pract, 2009, 83:106-116.
[128] Dhillon S, Weber J. Saxagliptin[J]. Drugs, 2009, 69:2103-2114. [129] Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in
patients with type 2 diabetes treated with metformin and a
82 ● 中国循证指南共识 ● 《中国医学前沿杂志（电子版）》
2015 年第 7 卷第 3 期
sulfonylurea[J]. Diabetes Care, 2005, 28:1083-1091.
[130] Gao Y, Yoon KH, Chuang LM, et al. Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes in adequately controlled with metformin or metformin and a sulphonylurea[J]. Diabetes Res Clin Pract, 2009, 83:69-76. [131] Yang W, Chen L, Ji Q, et al. Liraglutide provides similar glycemic control asglimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial[J]. Diabetes Obes Metab, 2011, 13:81-88. [132] Ji L, Li H, Guo X, et al. Impact of base line BMI on glycemic control and weight change with metformin monotherapy in Chinese type 2 diabetes patients: phase Ⅳ open-label trial[J]. PLoS One, 2013, 8:e57222.
[133] Hong J, Zhang Y, Lai S, et al. Response to comment on Hong et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease[J]. Diabetes Care, 2014, 37:e21.
[134] National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update[J]. Am J Kidney Dis, 2012, 60:850-886.
[135] Hirst JA, Farmer AJ, Dyar A, et al. Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis[J]. Diabetologia, 2013, 56:973-984.
[136] Ji L, Tong X, Wang H, et al. Effcacy and safety of traditional Chinese medicine for diabetes: a double-blind, randomised, controlled trial: evidence-based medical research of Xiaoke Pill study group[J]. PLoS One, 2013, 8:e56703.
[137] Zhu XX, Pan CY, Li GW, et al. Addition of rosiglitazone to existing sulfonylurea treatment in Chinese patients with type 2 diabetes and exposure to hepatitis B or C[J]. Diabetes Technol Ther, 2003, 5:33-42.
[138] Phatak HM, Yin DD. Factors associated with the effect-size of thiazolidinedione (TZD) therapy on HbA(1c): a meta-analysis of published randomized clinical trials[J]. Curr Med Res Opin, 2006, 22:2267-2278.
[139] Hernandez AV, Usmani A, Rajamanickam A, et al. Thiazolidinediones and risk of heart failure in patients with or at high
risk of type 2 diabetes mellitus: a meta-analysis and metaregression analysis of placebo-controlled randomized clinical
trials[J]. Am J Cardiovasc Drugs, 2011, 11:115-128.
[140] Landgraf R. Meglitinide analogues in the treatment of type 2 diabetes mellitus[J]. Drugs Aging, 2000, 17:411-425. [141] 蔡晓凌，周灵丽，罗樱樱，等．瑞格列奈在中国 2 型糖尿 病患者中疗效及安全性的荟萃分析 [J]．中国糖尿病杂志， 2013， 21 ： 907-912．
[142] 蔡晓凌，罗樱樱，韩学尧，等．那格列奈在亚洲 2 型糖尿 病患者中疗效及安全性的荟萃分析 [J]．中国糖尿病杂志， 2013， 21 ： 913-917．
[143] Wang W, Bu R, Su Q, et al. Randomized study of repaglinide alone and in combination with metformin in Chinese subjects with type 2 diabetes na?ve to oral antidiabetes therapy[J]. Expert Opin Pharmacother, 2011, 12:2791-2799.
[144] 陈璐璐，郑涓．阿卡波糖、二甲双胍、格列吡嗪在新诊断
青年 2 型糖尿病患者中应用的比较 [J]．中华内分泌代谢杂 志， 2004， 20 ： 449-450．
[145] Pan CY, Landen H. Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in China[J]. Clin Drug Invest, 2007, 27:397-405.
[146] 潘长玉，姬秋和，杨文英，等． 2 型糖尿病患者维格列汀 与阿卡波糖单药治疗的比较研究——24 周多中心、随机、 双盲、双模拟、阳性对照试验 [J]．中华内分泌代谢杂志， 2009， 25 ： 386-390．
[147] Yang W, Liu J, Shan Z, et al. Acarbose compared with metformin asinitial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomized trial[J]. Lancet Diabetes Endocrinol, 2014, 2:46-55.
[148] Cai X, Han X, Luo Y, et al. Comparisons of the Efficacy of alpha glucosidase inhibitors on type 2 diabetes patients between Asian and Caucasian[J]. PLoS One, 2013, 8:e79421.
[149] Hsieh CJ. Acarbose reduces the risk of pre-lunch hypoglycemia in elderly people with diabetes eating rice porridge for breakfast[J]. Diabetes Res Clinical Pract, 2010:89:e66-68.
[150] Meneilly GS, Ryan EA, Radiziuk J, et al. Effect of acarbose on insulin sensitivity in elderly patients with diabetes[J]. Diabetes Care, 2000, 23:1162-1167.
[151] Josse RG, Chiasson JL, Ryan EA, et al. Acarbose in the treatment of elderly patients with type 2 diabetes[J]. Diabetes Res Clin Pract, 2003, 59:37-42.
[152] Pan C, Xing X, Han P, et al. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus[J]. Diabetes Obes Metab, 2012, 14:737-744.
[153] Pan C,Yang W, Barona JP, et al. Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial[J]. Diabet Med, 2008, 25:435-441.
[154] 中华医学会糖尿病学分会．基于胰高血糖素样肽 1 降糖药物 的临床应用共识 [J]．中华糖尿病杂志， 2014， 6 ： 14-20．
[155] McEwan P, Poole CD, Tetlow T, et al. Evaluation of the costeffectiveness of insulin glargine versus NPH insulin for the
treatment of type 2 diabetes in the UK[J]. Curr Med Res Opin, 2007, 23 Suppl 1:S21-31.
[156] Oliveira JH, Ji LN, Landry J, et al. Initiation and intensifcation with 75% insulin lispro protamine suspension, 25% insulin lispro (LM75/25) is noninferior to glargine plus lispro (G+L) in patients with type 2 diabetes (T2D) : results of the PARADIGM Study[J]. Diabetes, 2010, 59:628-636.
[157] Richter B, Neises G.‘Human’insulin versus animal insulin in people with diabetes mellitus[J]. Cochrane Database Syst Rev, 2005, 25:CD003816.
[158] Pan CY, Sinnassamy P, Chung KD, et al. Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients[J]. Diabetes Res Clin Pract, 2007, 76:111-118.
[159] Siebenhofer A, Plank J, Berghold A, et al. Short acting insulin analogues versus regular human in sulin in patients with diabetes
《中国医学前沿杂志（电子版）》 2015 年第 7 卷第 3 期 ● 中国
循证指南共识 ● 83
mellitus[J]. Cochrane Database Syst Rev, 2006, 19:CD003287.
[160] Goudswaard AN, Furlong NJ, Valk GD, et al. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic
agents in patients with type 2 diabetes mellitus[J]. Cochrane Database Syst Rev, 2004, 18:CD003418.
[161] Raskin P, Matfn G, Schwartz SL, et al. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study
(Achieving Control Through Insulinplus Oralage Nts)[J]. Diabetes Obes Metab, 2009, 11:27-32.
[162] Misso ML, Egberts KJ, Page M, et al. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus[J]. Cochrane Database Syst Rev, 2010, 20:CD005103.
[163] Pickup JC, Renard E. Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes[J]. Diabetes Care, 2008, Suppl 2:S140-145.
[164] Jeitler K, Horvath K, Berghold A, et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections
in patients with diabetes mellitus: systematic review and metaanalysis[J]. Diabetologia, 2008, 51:941-951.
[165] Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, orthrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study)[J]. Diabetes Obes Metab, 2006, 8:58-66.
[166] Yang W, Ji Q, Zhu D, et al. Biphasic insulin aspart 30 three times daily is more effective than at wice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs[J]. Diabetes Care, 2008, 31:852-856.
[167] Yang W, Jinnouchi H. BIAsp 30 once daily is well tolerated and non-inferior to insulin glargine once daily both in combination with metformin and glimepiride in Chinese and Japanese subjects with type 2 diabetes[J]. Diabetes, 2012, 61 Suppl 1:S622. [168] Bowering K, Reed VA, Felicio JS, et al. A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study[J]. Diabet Med, 2012, 29:e263-272.
[169] 中华医学会糖尿病分会．新诊断 2 型糖尿病患者短期胰 岛素强化治疗专家共识 [J]．中华医学杂志， 2013， 93 ： 1524-1526.
[170] Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes[J]. N Engl J Med, 2007, 357:1716-1730.
[171] Dixon JB, Zimmet P, Alberti KG, et al. Bariatric surgery: an IDF statement for obese type 2 diabetes[J]. Diabet Med, 2011, 28:628-642.
[172] 中华医学会糖尿病学分会，中华医学会外科学分会．手 术治疗糖尿病专家共识 [J]．中华糖尿病杂志， 2011， 3 ： 205-208．
[173] Arterburn D, Schauer DP, Wise RE, et al. Change inpredicted 10-year cardiovascular risk following laparoscopic Roux-en-Y gastric by pass surgery[J]. Obes Surg, 2009, 19:184-189. [174] Ramos AC, Galvao Neto MP, de Souza YM, et al. Laparoscopic duodenal-jejunal exclusion in the treatment of type 2 diabetes mellitus in patients with BMI ＜ 30 kg/m2
(LBMI)[J]. Obes
Surg, 2009, 19:307-312.
[175] Flum DR, Belle SH, King WC, et al. Perioperative safety in the longitudinal assessment of bariatric surgery[J]. N Engl J Med, 2009, 361:445-454.
[176] Rosenthal R, Li X, Samuel S, et al. Effect of sleeve gastrectomy on patients with diabetes mellitus[J]. Surg Obes Relat Dis, 2009, 5:429-434.
[177] Rubino F, Kaplan LM, Schauer PR, et al. The diabetes surgery
summit consensus conference: recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus[J]. Ann Surg, 2010, 251:399-405.
[178] Dixon JB, le Roux CW, Rubino F, et al. Bariatric surgery for type 2 diabetes[J]. Lancet, 2012, 379:2300-2311.
[179] Abbatini F, Capoccia D, Casella G, et al. Type 2 diabetes in obese patients with body mass index of 30-35 kg/m: sleeve
gastrectomy versus medical treatment[J]. Surg Obes Relat Dis, 2012, 8:20-24.
[180] Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes[J]. N Engl J Med, 2012, 366:1567-1576.
[181] Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes[J]. N Engl J Med, 2012, 366:1577-1585.
[182] 刘兴振，邹大进．胃肠减重手术围手术期管理要点 [J]．中 国实用内科杂志， 2012， 32 ： 754-756．
[183] 纪立农．手术治疗 2 型糖尿病 ：证据和立场 [J]．中国糖尿 病杂志， 2012， 20 ： 241-244．
[184] Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy[J]. N Engl J Med, 2005, 352:341-350. [185] Work group on Hypoglycemia, American Diabetes Association. Defning and reporting hypoglycemia indiabetes: a report from
the American Diabetes Association Work group on Hypoglycemia[J]. Diabetes Care, 2005, 28:1245-1249.
[186] Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study[J]. BMJ, 2010, 340:b4909.
[187] Lu B, Wen J, Song XY, et al. High prevalence of albuminuria in population based patients diagnosed with type 2 diabetes in the Shanghai downtown[J]. Diabetes Res Clin Pract, 2007, 75:184-192. [188] Mogensen CE. Microalbuminuria as a predictor of clinical diabetic nephropathy[J]. Kidney Int, 1987, 31:673-689. [189] Lu B, Song X, Dong X, et al. High prevalence of chronic kidney disease in population based patients diagnosed with type 2 diabetes in downtown Shanghai[J]. J Diabetes Complications, 2008, 22:96-103.
[190] Lu B, Gong W, Yang Z, et al. An evaluation of the diabetic kidney disease definition in Chinese patients diagnosed with type 2 diabetes mellitus[J]. J Int Med Res, 2009, 37:1493-1500.
[191] Tervaert TW, Mooyaart AL, Amann K, et al. Pathologic classifcation of diabetic nephropathy[J]. J Am Soc Nephrol, 2010,
84 ● 中国循证指南共识 ● 《中国医学前沿杂志（电子版）》
2015 年第 7 卷第 3 期
21:556-563.
[192] Ma YC, Zuo L, Chen JH, et al. Modifed glomerular fltration rate estimating equation for Chinese patients with chronic kidney disease[J]. J Am Soc Nephrol, 2006, 17:2937-2944. [193] Dong X, He M, Song X, et al. Performance and comparison of the Cockcroft-Gault and simplifed modifcation of Diet in
Renal Disease formulae in estimating glomerular fltrationrateina Chinese Type 2 diabetic population[J]. Diabet Med, 2007, 24:1482-1486.